Genfit SA is venturing into nearly untapped territory by launching a program in children with nonalcoholic steatohepatitis (NASH) with elafibranor, its dual PPAR alpha/delta agonist.
With more than two decades of experience in immunology and inflammatory diseases, Anthony Coyle was hankering for the opportunity to shift the treatment paradigm from systemic immunosuppressives, which temper disease but come with long-term consequences to patients, to "a different type of approach" that would modulate the immune system.
John Rice is a veteran of the annual J.P. Morgan Healthcare Conference (JPM), dating back to the days when it was known as Hambrecht & Quist. He's accustomed to the frenetic pace of the San Francisco event that kicks off the year for biopharma and, increasingly, for the larger life sciences universe. What's different from those early years is the number of costume changes he makes during the week as director of life sciences at Cincytech.
SAN FRANCISCO – Sophie Kornowski-Bonnet wasn't on the same stage that Glaxosmithkline plc CEO Emma Walmsley commanded a day earlier at the 36th Annual J.P. Morgan Healthcare Conference, but the standing-room-only crowd was equally eager to hear the thoughts of the Roche Holding AG official on the future of biopharma development and on her pioneering role as one of the industry's top female business development chiefs.
SAN FRANCISCO – One of the hottest tickets in town Wednesday at the 36th Annual J.P. Morgan Healthcare Conference took place far from the hallways of the Westin St. Francis, as Women in Bio and Bloomberg Intelligence hosted an all-female panel of investors and industry executives who discussed the capital markets and their impact on biopharma development and commercialization.
SAN FRANCISCO – From angel investors to big pharma partners to corporate VCs, life sciences entrepreneurs got an earful about what to do – and what to avoid – when seeking funding and building relationships during the Redefining Early Stage Investments (RESI) conference and partnering forum in San Francisco, held in conjunction with the 36th Annual J.P. Morgan Healthcare Conference.
SAN FRANCISCO – Last year was a mixed bag for biopharma dealmaking, and not just by the numbers. Lofty valuations tamped down M&A, with buy-side companies also awaiting the outcome of U.S. tax reform. Oncology assets continued to rule, although first-in-class approvals actually showed a decline.
Two weeks before the start of the 36th annual J.P. Morgan (JPM) Healthcare Conference, the annual gauge of life sciences investor sentiment, organizers caused a firestorm with their decision to bar media from the breakout sessions that follow canned presentations by 480 public and private companies over the four-day meeting. They relented 24 hours later, after media outlets took to Twitter to complain and stories in consumer press riled up retail investors, who publicly charged the forum with giving preferential treatment to institutional customers.
Two weeks before the start of the 36th annual J.P. Morgan (JPM) Healthcare Conference, the annual gauge of life sciences investor sentiment, organizers caused a firestorm with their decision to bar media from the breakout sessions that follow canned presentations by 480 public and private companies over the four-day meeting. They relented 24 hours later, after media outlets took to Twitter to complain and stories in consumer press riled up retail investors, who publicly charged the forum with giving preferential treatment to institutional customers.
